Biontech US Inc.

The General Hospital Corporation

Massachusetts Institute of Technology

Dana-farber-cancer Institute Inc.

The Broad Institute, Inc.

Michael Steven Rooney

Nir Hacohen

Jennifer Grace Abelin

Dominik Barthelme

Rob Carl Oslund

Edward F Fritsch

Catherine J Wu

Robert Kamen

Sachet Ashok Shukla

Jing Sun

Pavan Bachireddy

The field of the present invention relates to immunotherapeutic peptides, peptide binding agents, and their use, for example, in the immunotherapy of cancer.

Protein antigens and uses thereof

Systems, compositions, and methods for isolating HLA-peptides from cells. A universal platform and methods for profiling the HLA-peptidome, enabling identification of endogenously presented HLA-peptides from cell lines expressing any possible class I or II construct.

HLA-based methods and compositions and uses thereof

In one aspect, provided herein is a method comprising: (a) (i) determining cytolytic activity in a tumor from the subject; and/or (ii) determining genetic alterations associated with cytolytic activity in the tumor; and (b) administering an immunotherapeutic agent to the subject if (i) cytolytic activity is detected in the tumor and/or (ii) a genetic alteration associated with induction of cytolytic activity, tumor resistance to cytolytic activity and/or suppression of cytolytic activity is detected in the tumor.

Molecular biomarkers for cancer immunotherapy

Compositions and methods for isolating HLA-peptides from cells. A universal platform and methods for profiling the HLA-peptidome, enabling identification of endogenously presented HLA-peptides from cell lines expressing any possible class I or II construct.

Methods for preparing a personalized cancer vaccine and a method to train a machine-learning HLA-peptide presentation prediction model.

Method and systems for prediction of HLA class II-specific epitopes and characterization of CD4+ T cells

Disclosed herein in one aspect is a pharmaceutical composition comprising a plurality of neoantigenic peptides and a pharmaceutically acceptable carrier, each neoantigenic peptide comprising a tumor-specific neoepitope capable of binding to an HLA protein in a subject, each tumor-specific neoepitope comprising a tumor-specific mutation present in a tumor, wherein (a) the composition comprises neoantigenic peptides comprising tumor-specific mutations present in at least 1% of subjects in a population of subjects suffering from cancer; (b) the composition comprises neoantigenic peptides comprising tumor-specific neoepitopes which bind to HLA proteins present in at least 5% of subjects in the population; and (c) the composition comprises at least one neoantigenic peptide capable of eliciting an immune response against a tumor present in at least 5% of the subjects in the population of subjects suffering from cancer.

Growing community of inventors

Boston, MA, United States of America

Michael Steven Rooney